Fortis Healthcare Ltd - 532843 - Certificate Under Regulation 40 (10) Of SEBI (Listing Regulations And Disclosure Requirements) Regulation, 2015
Pursuant to Regulation 40(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith a Certificate received from M/s. Mukesh Agarwal & Co., Company Secretaries, for the half-year ended on March 31, 2021. You are requested to take the same on your record. FORTIS HEALTHCARE LTD. - 532843 - Regulation 30 Of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.
This is in continuation of our intimation dated October 18, 2018, December 22, 2018, March 20, 2019 November 13, 2020 and November 21, 2020 with respect to an ad-interim ex-parte order passed by SEBI in the matter relating to the alleged diversion of funds from the Company by its erstwhile promoters. SEBI has issued a notice under Rule 4 of SEBI (Procedure for holding inquiry and imposing penalties) Rules, 1995 read with Section 15-I of Securities and Exchange Board of India Act, 1992 in the matter of Fortis Healthcare Limited to, among others, Escorts Heart Institute and Research Center Limited (EHIRCL), a wholly owned subsidiary of the Company. The notice was received by EHIRCL on April 15, 2021. The management and Board of the Company that was newly constituted after NTK Ventures Pte. Ltd. (a wholly owned subsidiary of IHH Healthcare Berhad) became promoters of the Company, are evaluating the notice received by EHIRCL, in consultation with its legal advisors. FORTIS HEALTHCARE LTD. - 532843 - Compliance Certificate- Regulation 7(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - For Half Year Ended March 31, 2021
Pursuant to Regulation 7(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Compliance Certificate certifying the compliance with the requirement of Regulation 7(2) for the half year ended March 31, 2021.
Fortis Health's prospects healthy on improved hospitals, diagnostics biz outlook
Revenues will likely grow 9.6% YoY, with operating profits expected to surge 62.3%, indicating improved efficiencies. Analysts said Fortis is also likely to report a rise in growth led by higher profitability in its diagnostics business Fortis Healthcare Ltd - 532843 - Shareholding for the Period Ended March 31, 2021
Fortis Healthcare Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2021. For more details, kindly Click here Fortis Healthcare Ltd - 532843 - Statement Of Investor Complaints For The Quarter Ended March 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 017170 Name of the Signatory :- SUMIT GOELDesignation :- Company Secretary and Compliance Officer FORTIS HEALTHCARE LTD. - 532843 - Statement Of Investor Complaints For The Quarter Ended March 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 017170 Name of the Signatory :- SUMIT GOELDesignation :- Company Secretary and Compliance Officer
Delhi private hospitals to reserve 30% ICU beds for Covid patients
The order has been given to 54 large private hospitals and hospital chains, including Indraprastha Apollo Hospital, Sir Ganga Ram Hospital, Max Healthcare and Fortis Healthcare. Fortis Healthcare Ltd - 532843 - Outcome Of The Board Meeting.
Dear Sir(s), Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today, inter-alia, considered and approved the appointment of Mr. Joerg Ayrle (DIN- 09128449), as an Additional Director (Non-Executive) of the Company with immediate effect. He will hold the office up to the next Annual General Meeting and will be regularized subject to the approval of the shareholders. Brief Profile of Mr. Joerg Ayrle is attached as Annexure 1. Further, there is no inter-se relationship between Mr. Joerg Ayrle and other Directors. Mr. Joerg Ayrle has declared that he is not debarred from accessing the capital markets and / or restrained from holding any position / office of Director in a Company pursuant to order of SEBI or any other such authority. The Board Meeting commenced at 1200 Hours and concluded at 1735 Hours. Fortis Healthcare Ltd - 532843 - Update On Acquisition Of Balance 50% Stake In DDRC SRL Diagnostics Private Limited
This is in continuation to our letter dated February 5, 2021 regarding acquisition of balance 50% stake in DDRC SRL Diagnostics Private Limited, wherein the indicative timelines for completion was mentioned as March 31, 2021. Please be informed that concerned parties have now mutually agreed to consummate the aforesaid transaction on or before April 15, 2021. This is for your information.